| Literature DB >> 31956395 |
Zahra Rahmani1, Majid Mojarrad2, Meysam Moghbeli2.
Abstract
BACKGROUND: Cancer is associated with various genetic and environmental risk factors. Beside the mutations or aberrant expression of protein-coding genes, the genetic deregulation of non-coding RNAs has also an important role during tumor progression and metastasis. Long non-coding RNAs (lncRNAs) are a class of ncRNAs larger than 200 nucleotides that may function as tumor-suppressor or oncogene. MAIN BODY: There is a raising trend of cancer incidence among Iranian population during the last decades. Therefore, it is required to prepare a general population specific panel of genetic markers for the early detection of cancer in this population. The tissue-specific expression characteristics and high stability in body fluids highlight the lncRNAs as efficient diagnostic and prognostic noninvasive biomarkers in cancer. In present review we summarized all of the lncRNAs which have been reported until now in different tumors among Iranian patients.Entities:
Keywords: Cancer; Diagnostic panel; Early detection; Iran; LncRNA
Year: 2020 PMID: 31956395 PMCID: PMC6961246 DOI: 10.1186/s13578-020-0373-0
Source DB: PubMed Journal: Cell Biosci ISSN: 2045-3701 Impact factor: 7.133
Fig. 1Molecular mechanisms and target genes of lnRNAs
All of the long non coding RNAs involved in tumor progressions among Iranian patients
| Study (et al.) | Year | Type | Gene | Population | Results |
|---|---|---|---|---|---|
| Shahryari [ | 2014 | ESCC | SOX2OT | 36 N/Ta | Over expression |
| Rezaei [ | 2016 | Esophageal, ovarian, cervical, breast, sarcoma, colon, and melanoma | LINC-ROR | 27 N/T | Esophageal, ovarian, and cervical cancers had over expressions while breast, sarcoma, colon, and melanoma had under expressions |
| Sahebi [ | 2016 | ESCC | LINC-ROR | 30 N/T | Over expression |
| Rahimnia [ | 2018 | ESCC | lnc-POU3F3 | 32 patients 32 controls | Over expression |
| Razavi [ | 2019 | ESCC | lnc-PCAT-1 | 75 N/T | Over expression |
| Bayat [ | 2018 | Prostate | Prcat17.3, Prcat38, Cat2184.4 | 30 N/T | Prcat17.3 and Prcat38 over expressions and Cat2184.4 under expression |
| Taheri [ | 2017 | Prostate | HOTAIR | 128 patients 250 controls | Polymorphism was correlated with tumor progression |
| Taheri [ | 2017 | Prostate | ANRIL | 125 patients 220 controls | Polymorphism was correlated with tumor progression |
| Sattarifard [ | 2017 | Prostate | PRNCR1 | 178 patients 180 BPHb | Polymorphism was correlated with tumor progression |
| Yazarlou [ | 2018 | Bladder | LINC00355, UCA1-203, MALAT1, and UCA1-201 | 59 patients 24 controls | LINC00355, UCA1-203, and MALAT1 over expressions. UCA1-201 under expression |
| Farhangian [ | 2018 | Gastric | SOX2OT | 33 N/T | Under expression |
| Hajjari [ | 2013 | Gastric | HOTAIR | 31 N/T | Over expression |
| Emadi-Andani [ | 2014 | Gastric | HOTAIR | 60 N/T | Over expression |
| Baratieh [ | 2017 | Gastric | PlncRNA-1 and TUG1 | 70 N/T | Over expression |
| Aminian [ | 2019 | Gastric | GAS5 | 130 patients 230 controls | Polymorphism was correlated with tumor progression |
| Kangarlouei [ | 2019 | Gastric | ANRIL and ANRASSF1 | 39 N/T | Over expression |
| Iranpour [ | 2016 | Breast | SOX2OT, PTPRG-AS1, ANRASSF1, and ANRIL | 38 N/T | Over expression |
| Hassanzarei [ | 2017 | Breast | HOTAIR | 220 patients 231 controls | Polymorphism was correlated with tumor progression |
| Hassanzarei [ | 2017 | Breast | H19 | 230 patients 240 controls | Polymorphism was correlated with tumor progression |
| Safari [ | 2019 | Breast | H19 | 111 patients 130 controls | Polymorphism was correlated with tumor progression |
| Abdollahzadeh [ | 2019 | Breast | H19 | 150 patients 100 controls | Polymorphism was correlated with tumor progression |
| Arshi [ | 2018 | Breast | MALAT1, SRA, NEAT1, and GAS5 | 23 patients 15 controls | MALAT1, SRA, and NEAT1 over expressions. GAS5 under expression |
| Soleimanpour [ | 2018 | Breast | PRNCR1 | 30 N/T | Over expression |
| Ravanbakhsh [ | 2019 | Breast | lncUSMycN | 52 N/T | Over expression |
| Rezanejad Bardaji [ | 2018 | Colorectal | ZEB1-AS1 | 32 N/T | Over expression |
| Kazemzadeh [ | 2017 | Colorectal | LOC100287225 | 30 N/T | Under expression |
| Kazemzadeh [ | 2016 | Colorectal | LOC100287225 | 39 N/T | Under expression |
| Rezanejad bardaji [ | 2018 | Colorectal | VIM-AS1 | 35 N/T | Over expression |
| Hashemi [ | 2016 | ALL | lnc-LAMC2-1:1 | 110 patients 120 controls | Polymorphism was correlated with tumor progression |
| Esfandi [ | 2018 | Lung | OIP5-AS | 32 N/T | Under expression |
aTumor tissues and normal margins
bBenign prostatic hyperplasia
Fig. 2All of the long noncoding RNAs which are involved in tumor progression among Iranian population